Dataset Information

Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol.

ABSTRACT: Glioblastoma multiform (GBM) is by far the most malignant glioma. We have introduced a new treatment for GBMs that comprises the inhalation of a naturally occurring terpene with chemotherapeutic properties known as perillyl alcohol (POH). Clinical trial results on recurrent GBM patients showed that POH extends the average life by more than eight months, temporarily slows tumor growth, and in some cases even decreases tumor size. After approximately seven months, the tumor continues to grow and leads to a dismal prognosis. To investigate how these tumors become resistant to POH, we generated an A172 human glioblastoma cell culture tolerant to 0.06 mM of POH (A172r). We used Multidimensional Protein Identification Technology (MudPIT) to compare the protein expression profile of A172r cells to the established glioblastoma A172 cell line. Our results include a list of identified proteins unique to either the resistant or the nonresistant cell line. These proteins are related to cellular growth, negative apoptosis regulation, Ras pathway, and other key cellular functions that could be connected to the underlying mechanisms of resistance.

SUBMITTER: de Saldanha da Gama Fischer J

PROVIDER: S-EPMC3017632 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol.

de Saldanha da Gama Fischer Juliana J Costa Carvalho Paulo P da Fonseca Clovis Orlando CO Liao Lujian L Degrave Wim M WM da Gloria da Costa Carvalho Maria M Yates John R JR Domont Gilberto B GB

Journal of proteome research 20100927 1

Glioblastoma multiform (GBM) is by far the most malignant glioma. We have introduced a new treatment for GBMs that comprises the inhalation of a naturally occurring terpene with chemotherapeutic properties known as perillyl alcohol (POH). Clinical trial results on recurrent GBM patients showed that POH extends the average life by more than eight months, temporarily slows tumor growth, and in some cases even decreases tumor size. After approximately seven months, the tumor continues to grow and l ...[more]

PMID: 20806975

Similar Datasets

Project description:Polymorphisms in MTHFR gene influence risk and overall survival of patients with brain tumor. Global genomic DNA (gDNA) methylation profile from tumor tissues is replicated in peripheral leukocytes. This study aimed to draw a correlation between rs1801133 MTHFR variants, gDNA methylation and overall survival of patients with recurrent glioblastoma (rGBM) under perillyl alcohol (POH) treatment. gDNA from whole blood was extracted using a commercially available kit (Axygen) and quantified by spectrophotometry. Global gDNA methylation was determined by ELISA and rs1801133 polymorphism by PCR-RFLP. Statistical analysis of gDNA methylation profile and rs1801133 variants included Mann-Whitney, Kruskal-Wallis, Spearman point-biserial correlation tests (SPSS and Graphpad Prism packages; significant results for effect size higher than 0.4). Prognostic value of gDNA methylation and rs1801133 variants considered survival profiles at 25?weeks of POH treatment, having the date of protocol adhesion as starting count and death as the final event. Most rGBM patients showed global gDNA hypomethylation (median?=?31.7%) and a significant, moderate and negative correlation between TT genotype and gDNA hypomethylation (median?=?13.35%; rho?=?-?0.520; p?=?0.003) compared to CC variant (median?=?32.10%), which was not observed for CT variant (median?=?33.34%; rho?=?-?0.289; p?=?0.06). gDNA hypermethylated phenotype (median?=?131.90%) exhibited significant, moderate and negative correlations between TT genotype (median?=?112.02%) and gDNA hypermethylation levels when compared to CC (median?=?132.45%; rho?=?-?0,450; p?=?0.04) or CT (median?=?137.80%; rho?=?-?0.518; p?=?0.023) variants. TT variant of rs1801133 significantly decreased gDNA methylation levels for both patient groups, when compared to CC (d values: hypomethylated?=?1.189; hypermethylated?=?0.979) or CT (d values: hypomethylated?=?0.597; hypermethylated?=?1.167) variants. Positive prognostic for rGBM patients may be assigned to gDNA hypermethylation for survivors above 25?weeks of treatment (median?=?88?weeks); and TT variant of rs1801133 regardless POH treatment length. rGBM patients under POH-based therapy harboring hypermethylated phenotype and TT variant for rs1801133 had longer survival. Intranasal POH therapy mitigates detrimental effects of gDNA hypomethylation and improved survival of patients with rGBM harboring TT mutant variant for MTHFR rs1801133 polymorphism. CONEP -9681- 25,000.009267 / 2004. Registered 12th July, 2004.

Dataset Information

Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol.

Publications

Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure